{"id":454126,"date":"2021-03-09T16:04:22","date_gmt":"2021-03-09T21:04:22","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=454126"},"modified":"2021-03-09T16:04:22","modified_gmt":"2021-03-09T21:04:22","slug":"infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/","title":{"rendered":"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }\n.bwalignl { text-align: left }\n.bwblockalignl { margin-left: 0px; margin-right: auto }\n.bwcellpmargin { margin-bottom: 0px; margin-top: 0px }\n.bwnowrap { white-space: nowrap }\n.bwpadl0 { padding-left: 0px }\n.bwpadr0 { padding-right: 0px }\n.bwtablemarginb { margin-bottom: 10px }\n.bwuline { text-decoration: underline }\n.bwvertalignb { vertical-align: bottom }\n.bwvertalignt { vertical-align: top }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast<\/b><\/p>\n<p>CAMBRIDGE, Mass.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com%2F&amp;esheet=52393338&amp;newsitemid=20210309005959&amp;lan=en-US&amp;anchor=Infinity+Pharmaceuticals%2C+Inc.&amp;index=1&amp;md5=91f5584d19d506f6f746d39cfa16c5b8\">Infinity Pharmaceuticals, Inc.<\/a> (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, March 16, 2021 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2020 financial results and provide an update on eganelisib development.\n<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl\">\n<tr>\n<td class=\"bwpadl0 bwnowrap\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><strong><span class=\"bwuline\">Conference Call &amp; Webcast Details<\/span><\/strong><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><span class=\"bwuline\">Date:<\/span><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwalignl\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\nMarch 16, 2021\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><span class=\"bwuline\">Time:<\/span><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwalignl\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n4:30 pm Eastern Time\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><span class=\"bwuline\">Toll Free:<\/span><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwalignl\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(877) 316-5293\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><span class=\"bwuline\">International:<\/span><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwalignl\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n(631) 291-4526\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><span class=\"bwuline\">Conference ID:<\/span><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwpadl0 bwpadr0 bwvertalignb bwalignl\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\">\n7174736\n<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwpadl0\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin\"><span class=\"bwuline\">Webcast:<\/span><\/p>\n<\/td>\n<td rowspan=\"1\" colspan=\"1\" \/>\n<td class=\"bwvertalignb bwpadl0 bwalignl\" rowspan=\"1\" colspan=\"1\">\n<p class=\"bwcellpmargin bwalignl\"><a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2F24t7wsio&amp;esheet=52393338&amp;newsitemid=20210309005959&amp;lan=en-US&amp;anchor=https%3A%2F%2Fedge.media-server.com%2Fmmc%2Fp%2F24t7wsio&amp;index=2&amp;md5=6c60247b8d2eda5e7ad5fc14969c818d\">https:\/\/edge.media-server.com\/mmc\/p\/24t7wsio<\/a><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p><i>A live webcast of the conference call can be accessed in the Investors\/Media section of Infinity&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com%2F&amp;esheet=52393338&amp;newsitemid=20210309005959&amp;lan=en-US&amp;anchor=www.infi.com&amp;index=3&amp;md5=a84640cecf1bd13755923b475d3b9dfb\">www.infi.com<\/a>. An archived version of the webcast will be available on Infinity&#8217;s website for 30 days.<\/i><\/p>\n<p><b>About Infinity and eganelisib <\/b><\/p>\n<p>\nInfinity is a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled study of eganelisib combined with Opdivo<sup>\u00ae<\/sup> in I\/O na\u00efve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq<sup>\u00ae<\/sup> and Abraxane<sup>\u00ae<\/sup> in front-line TNBC and in combination with Tecentriq and Avastin<sup>\u00ae<\/sup> in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil<sup>\u00ae<\/sup> in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I\/O-na\u00efve, and front-line and second line settings. For more information on Infinity, please refer to Infinity&#8217;s website at <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.infi.com&amp;esheet=52393338&amp;newsitemid=20210309005959&amp;lan=en-US&amp;anchor=www.infi.com&amp;index=4&amp;md5=f623e5c3ada4dcc95db1334d98a776fb\">www.infi.com<\/a>.\n<\/p>\n<p>\nOpdivo<sup>\u00ae<\/sup> is a registered trademark of Bristol Myers Squibb.<br \/>\n<br \/>Tecentriq<sup>\u00ae<\/sup> is a registered trademark of Genentech, Inc.<br \/>\n<br \/>Abraxane<sup>\u00ae<\/sup> is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.<br \/>\n<br \/>Avastin<sup>\u00ae<\/sup> is a registered trademark of Genentech, Inc.<br \/>\n<br \/>Doxil<sup>\u00ae<\/sup> is a registered trademark of Baxter Healthcare Corporation.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20210309005959\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20210309005959\/en\/<\/a><\/span><\/p>\n<p><b><span class=\"bwuline\">Investor Relations Contact<\/span>:<br \/>\n<\/b><br \/>Ashley R. Robinson | <i>Managing Director<br \/>\n<br \/><\/i><b>LifeSci Advisors, LLC<br \/>\n<\/b><br \/>617-430-7577 | <a rel=\"nofollow\" href=\"mailto:arr@lifesciadvisors.com\">arr@lifesciadvisors.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> United States North America Massachusetts<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Research Biotechnology Other Health Health Pharmaceutical General Health Other Science Science Oncology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\" \/>\n","protected":false},"excerpt":{"rendered":"<p>Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, March 16, 2021 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2020 financial results and provide an update on eganelisib development. Conference Call &amp; Webcast Details \u00a0 Date: March 16, 2021 Time: 4:30 pm Eastern Time Toll Free: (877) 316-5293 International: (631) 291-4526 Conference ID: 7174736 Webcast: https:\/\/edge.media-server.com\/mmc\/p\/24t7wsio A live webcast of the conference call &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-454126","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, March 16, 2021 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2020 financial results and provide an update on eganelisib development. Conference Call &amp; Webcast Details \u00a0 Date: March 16, 2021 Time: 4:30 pm Eastern Time Toll Free: (877) 316-5293 International: (631) 291-4526 Conference ID: 7174736 Webcast: https:\/\/edge.media-server.com\/mmc\/p\/24t7wsio A live webcast of the conference call &hellip; Continue reading &quot;Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-09T21:04:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast\",\"datePublished\":\"2021-03-09T21:04:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/\"},\"wordCount\":418,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/\",\"name\":\"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2021-03-09T21:04:22+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/","og_locale":"en_US","og_type":"article","og_title":"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast - Market Newsdesk","og_description":"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast CAMBRIDGE, Mass.&#8211;(BUSINESS WIRE)&#8211;Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, will host a conference call on Tuesday, March 16, 2021 at 4:30 p.m. ET to report its financial results for the fourth quarter and full year 2020 financial results and provide an update on eganelisib development. Conference Call &amp; Webcast Details \u00a0 Date: March 16, 2021 Time: 4:30 pm Eastern Time Toll Free: (877) 316-5293 International: (631) 291-4526 Conference ID: 7174736 Webcast: https:\/\/edge.media-server.com\/mmc\/p\/24t7wsio A live webcast of the conference call &hellip; Continue reading \"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-09T21:04:22+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast","datePublished":"2021-03-09T21:04:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/"},"wordCount":418,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/","name":"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2021-03-09T21:04:22+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20210309005959r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/infinity-announces-the-date-of-its-fourth-quarter-and-full-year-2020-financial-results-conference-call-and-webcast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Infinity Announces the Date of Its Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=454126"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/454126\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=454126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=454126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=454126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}